Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can an immune booster keep liver cancer away after surgery?

NCT ID NCT07553767

Disease control Sponsor: Ningbo No.2 Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study will test whether adding peginterferon alfa-2b to standard antiviral drugs can help prevent hepatitis B-related liver cancer from coming back after surgery. About 156 adults aged 18 to 65 will receive either the combination or antivirals alone. Researchers will track cancer recurrence, survival, and hepatitis B markers for up to 5 years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Peginterferon alfa-2b (a protein injection that boosts the immune system) combined with antiviral drugs (tenofovir or similar)
What this could lead to
If it works, this combination could lower the chance of liver cancer coming back after surgery and improve long-term survival for people with hepatitis B-related liver cancer.
What could go wrong
This is a very early (Phase 1) study with only 156 people, so results are uncertain. Peginterferon can cause flu-like symptoms, fatigue, and mood changes, and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 156 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Dec 2035

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 65 years, male or female. * Confirmed diagnosis of hepatitis B virus-related hepatocellular carcinoma (HCC) by pathology or contrast-enhanced CT/MRI. * Underwent radical resection or local ablation therapy; CNLC (Chinese Liver Cancer Classification) stage Ia, Ib, or IIa; no residual tumor confirmed by imaging within 1-3 months postoperation. * HBsAg positive and HBsAg level \< 2000 IU/mL. * No prior systemic chemotherapy, immunotherapy, or targeted therapy before enrollment. * Able to provide written informed consent and comply with the follow-up schedule. * For women of childbearing potential: negative pregnancy test and effective contraception during treatment and for 24 weeks after the last dose. Exclusion Criteria: * Recurrent or metastatic HCC at enrollment. * Contraindication to peginterferon alfa-2b treatment. * WBC \< 3.5×10⁹/L or platelet count \< 100×10⁹/L. * ALT \> 3×ULN or total bilirubin (TBIL) \> 2×ULN. * Child-Pugh score \> 5 points. * INR \> 1.5. * History of organ transplantation or planned transplantation. * Hypersensitivity to peginterferon alfa-2b or any excipient of the study drug. * Pregnant or breastfeeding women. * Participation in another interventional clinical trial. * History of significant alcoholism or drug abuse. * Genetic or metabolic liver disease (Wilson disease, hemochromatosis, etc.). * Coinfection with HAV, HCV, HEV, EBV, CMV , or other viral hepatitis that may interfere with study evaluation. * Unable to comply with study procedures and follow-up. * Other conditions deemed inappropriate by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatitis B chronic infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatitis B chronic infection Hepatitis B, chronic Hepatocellular carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ningbo Medical Center Lihuili Hospital

    Ningbo, Zhejiang, 315000, China

  • Ningbo Mingzhou Hospital (Affiliated to Zhejiang University)

    Ningbo, Zhejiang, 315000, China

  • Ningbo No.2 Hospital

    Ningbo, Zhejiang, 315000, China

  • Shulan (Hangzhou) Hospital

    Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.